Positive Topline Results for New Schizophrenia DrugPositive Topline Results for New Schizophrenia Drug
Once-monthly treatment with aripiprazole lauroxil, a new injectable, long-acting antipsychotic, significantly reduces positive and negative symptoms in schizophrenia patients. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 8, 2014 Category: Psychiatry Tags: Psychiatry News Source Type: news

Lundbeck And Otsuka Launch Abilify Maintena In Europe
H. Lundbeck A/S and Otsuka Pharmaceutical Europe Ltd. announced the European launch of Abilify Maintena (aripiprazole) following the approval by the European Commission last November 2013. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 19, 2014 Category: Pharmaceuticals Source Type: news

Health Canada approves Otsuka and Lundbeck's once-monthly Abilify Maintena
Health Canada has issued a notice of compliance for Otsuka and Lundbeck's Abilify Maintena, an intramuscular (IM) once-monthly injectable formulation, for the maintenance treatment of schizophrenia in stabilised adult patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 14, 2014 Category: Pharmaceuticals Source Type: news

Using Aripiprazole in Major Depressive DisorderUsing Aripiprazole in Major Depressive Disorder
The doses of aripiprazole required by patients in clinical practice are assessed in this study. Medscape Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2013 Category: Consumer Health News Tags: Psychiatry Viewpoint Source Type: news

Top 100 Selling Drugs Through September ReportedTop 100 Selling Drugs Through September Reported
Cholesterol-lowering rosuvastatin was the nation's most prescribed drug over the course of the last 12 months through September, and the antipsychotic aripiprazole racked up the highest sales. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 31, 2013 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

What If My Doctor Ignores Side Effects?
When a reader posted that she had severe side effects from Abilify and her psychiatrist refused to do anything about it, I took an in-depth look at all the issues ...Read Full Post (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - September 23, 2013 Category: Psychiatry Source Type: news

Japan's Otsuka to Acquire U.S. Firm Astex for $886M
Otsuka seeks to increase revenue streams as patents for its mainstay Abilify schizophrenia treatment will begin to expire (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 5, 2013 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: news

Abilify / Aripiprazole Side Effects
Abilify - generic name aripiprazole - is an atypical antipsychotic medication sometimes prescribed to treat schizophrenia and psychotic features of bipolar and schizoaffective disorders. People taking Abilify should be aware of the potential side effects. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - June 19, 2013 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news

Abilify / Aripiprazole Drug Profile
Abilify - generic Aripiprazole - is approved to treat schizophrenia and the manic and mixed episodes of bipolar disorder. It is also approved for maintenance use in bipolar disorder, and as adjunctive treatment in adults (only) with major depressive disorder. Article covers major warnings and side effects, therapeutic advantages and other key information. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - June 19, 2013 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news

Some Ideas for Handling Treatment-Resistant Bipolar Disorder
Bipolar disorder is being better understood each day. There is also ongoing research into its treatment. But successfully treating bipolar disorder can involve several medication trials, and it can take years to achieve remission. Even if remission is attained, recurrence is the rule — not the exception. It’s not uncommon for all first-line treatments to be exhausted. People in this situation may be considered by mental health professionals to be treatment-resistant. Luckily, there are treatments that can be tried when first-line, and even second-line, treatments for bipolar disorder fail. What is Treatment ...
Source: Psych Central - June 8, 2013 Category: Psychiatry Authors: Natasha Tracy Tags: Anticonvulsants Antidepressants Atypical Antipsychotics Bipolar Cognitive-Behavioral Disorders General Medications Mood Stabilizers Psychotherapy Treatment Abilify Aripiprazole Bipolar Disorder Clinicians Consensus Depakote Source Type: news

Some Ideas for Handling Treatment-Resistant Bipolar Disorder
Bipolar disorder is being better understood each day. There is also ongoing research into its treatment. But successfully treating bipolar disorder can involve several medication trials, and it can take years to achieve remission. Even if remission is attained, recurrence is the rule — not the exception. It’s not uncommon for all first-line treatments to be exhausted. People in this situation may be considered by mental health professionals to be treatment-resistant. Luckily, there are treatments that can be tried when first-line, and even second-line, treatments for bipolar disorder fail. What is Treatment ...
Source: Psych Central - June 8, 2013 Category: Psychiatry Authors: Natasha Tracy Tags: Anticonvulsants Antidepressants Atypical Antipsychotics Bipolar Cognitive-Behavioral Disorders General Medications Mood Stabilizers Psychotherapy Treatment Abilify Aripiprazole Bipolar Disorder Clinicians Consensus Depakote Source Type: news

Long-Acting Abilify Cuts Psych Admissions (CME/CE)
SAN FRANCISCO (MedPage Today) -- Schizophrenia patients switching from regular daily antipsychotic medications to a long-acting form of aripiprazole (Abilify Maintena) had markedly fewer hospitalizations. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 22, 2013 Category: Psychiatry Source Type: news

100 Top-Selling Drugs Report Released 100 Top-Selling Drugs Report Released
Acid blocker esomeprazole and antipsychotic drug aripiprazole remain the top-selling US prescription drugs. Sales climbed for oseltamivir because of a severe influenza season, according to Drugs.com. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2013 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Proteus Digital Health raises $45 million, inks clinical trials deal with Oracle
Redwood City, California-based Proteus Digital Health announced that it had raised $62.5 million in its latest round of funding led by Oracle with participation from existing investors Otsuka, Novartis, Sino Portfolio and others. MobiHealthNews reported on the first $17.5 million that Proteus raised for this round a year ago, so the $62.5 million includes an [...] (Source: mobihealthnews)
Source: mobihealthnews - May 1, 2013 Category: Information Technology Authors: Brian Dolan Tags: Uncategorized Abilify FDA clearances ingestible sensors Kaiser Permanente Ventures medication adherence Medtronic Oracle clinical trials Otsuka Proteus Biomedical Proteus Digital Health Source Type: news

When the First Treatment for Depression Doesn’t Work
When the first treatment you try for your depression doesn’t work, it can feel utterly painful. As it is, depression makes you feel hopeless and helpless. An ineffective intervention might feel like the final straw. But it’s actually not uncommon for the first treatment to be unsuccessful. In fact, about 40 to 50 percent of people don’t respond to the first antidepressant they’re prescribed, according to Jonathan E. Alpert, M.D., Ph.D, the associate director of the Massachusetts General Hospital Depression Clinical and Research Program and co-founder and co-director of the Depression and Anxiety Group Practice. Sti...
Source: Psych Central - April 20, 2013 Category: Psychiatry Authors: Margarita Tartakovsky, M.S. Tags: Depression Disorders General Medications Self-Help Treatment Antidepressant Bipolar Disorder Co Director Depression And Anxiety Depression Anxiety Depression Treatment Final Straw Group Practice Hyland Hypothyroidism Incorr Source Type: news